Schizophrenia is a serious mental disorder occurring mostly in late adolescence and early adulthood. The overall incidence rate of schizophrenia is about 1%. At present, the research and development of antipsychotics focuses on atypical antipsychotics. Eponidone is an atypical antipsychotic drug. It can not only effectively treat the positive symptoms of schizophrenia (hallucination, delusion, thinking disorder, hostility, suspicion and strange behavior), but also reduce the occurrence of extrapyramidal syndrome (EPS), but also improve the negative symptoms of schizophrenia (slow response, dull emotion and language, avoidance of social interaction and lack of attention).
Eponidone is an atypical antipsychotic drug, which is suitable for acute treatment of adult schizophrenia.
Eponidone is mainly used in the treatment of schizophrenia. Its approval to market marks a new opportunity for many schizophrenic patients who are only partially effective with existing drugs. This product can better control their symptoms.